Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients
Completed
- Conditions
- Colon Cancer
- Registration Number
- NCT00351572
- Lead Sponsor
- Alberta Health services
- Brief Summary
This study will determine whether a new diagnostic test called the Cell Search Assay can detect circulating colon cancer cells in patients who have had surgery for colon cancer and had visible cancer removed. Other parts of the study will look at whether the presence of the circulating tumor cells in blood predicts whether a patient will have their colon cancer return.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- stage II or III colon cancer
Exclusion Criteria
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the predictive value of circulating tumor cells (CTCs) in recurrence of stage II/III colon cancer?
How does the CellSearch Assay detect CTCs in post-surgical colon cancer patients with residual disease?
Are CTC counts associated with specific molecular subtypes of stage II/III colorectal adenocarcinoma?
What biomarkers correlate with CTC persistence in stage II/III colon cancer after curative resection?
How do CTC detection methods compare to traditional biomarkers like CEA in colon cancer monitoring?
Trial Locations
- Locations (1)
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Cross Cancer Institute🇨🇦Edmonton, Alberta, Canada